| Peptide-drug conjugates (PDCs) have emerged as a promising class of targeted therapeutics. Structurally similar to ADCs, PDCs differ in their homing device, offering unique advantages. A typical PDC is consists of three essential components: a homing peptide, a linker and a cytotoxic payload (Fig 1). The homing peptide includes targeting peptides and cell-penetrating peptides to guide the drug to its intended site. This structure design enables enhanced cell penetration, Reduced immunogenicity and cost-effective synthesis[1]. |
|
|
| Figure 1. A schematic structure of peptide–drug conjugates[1]. |
| While only a few PDCs, such as 177Lu-DOTATATE and 177Lu-PSMA-617, have gained approval, most remain in clinical development. Key challenges such as drug stability, efficacy, and administration methods require further optimization to expand therapeutic application, particularly in cancer treatment. |
 |
MedChemExpress: Your Partner in PDC Research |
|
| MedChemExpress provides a comprehensive range of custom services and products tailored to support your PDC research needs. |
| Product Service |
Description |
| XDC custom service |
One-stop custom services for ADCs, PDCs, POCs, XDC linkers, and more. |
| Peptide custom service |
Custom synthesis for linear peptides, cyclic peptides, fluorescent peptides, and peptide-chelator conjugates. |
| Product Name |
Description |
| Cyclo(RGDyK) |
A potent and selective αvβ3 integrin inhibitor. |
| Angiopep-2 hydrochloride |
A brain peptide vector for conjugation with anticancer agents, ideal for brain cancer research. |
| 7-O-(Amino-PEG4)-paclitaxel |
A Paclitaxel-linker conjugate for XDC synthesis. |
| DOTATATE |
A DOTA-conjugated peptide for PET imaging and peptide receptor radionuclide research. |
|
|
| Reference: |
| [1] Chem Soc Rev. 2021 Feb 15;50(3):1480-1494. |
|
 |
|
